Clinical Learning
Clinical 8: Type 2 diabetes – practical management principles
Individualised goals, cardiovascular and renal risk, medicines review and the 2026 NICE NG28 framework for adults with type 2 diabetes.
Clinical safety: Use current guidance, local policy and patient-specific judgement.
Learning objectives
• Apply individualised glycaemic and cardiovascular-risk management • Recognise that medicine choice is influenced by comorbid cardiovascular and renal disease • Use shared decision making when initiating or reviewing medicines • Recognise frailty, renal function and hypoglycaemia as key safety considerations • Know when to check the live 2026 NICE medicines framework
Clinical safety note
Type 2 diabetes medicines recommendations changed substantially in February 2026. Check the live NG28 medicines framework, current renal function, BNF/MHRA information and local formulary before prescribing or changing treatment.
A 2026-updated framework
NICE NG28 received a major medicines update in February 2026. Medicine choice now explicitly reflects not only glucose lowering but cardiovascular and renal benefit in important patient groups. Do not rely on older memorised “step 1, step 2” treatment sequences without checking the current guideline.
Individualised goals
Management includes structured education, dietary and lifestyle support, smoking cessation, cardiovascular risk management and glycaemic treatment. Agree goals with the person, taking account of age, frailty, comorbidity, hypoglycaemia risk, treatment burden and personal priorities.
Choosing and reviewing medicines
Current NG28 recommendations differ according to relevant comorbidities such as atherosclerotic cardiovascular disease, heart failure, chronic kidney disease and obesity-related priorities. SGLT-2 inhibitors and GLP-1 receptor agonists may be selected for cardiovascular or renal benefit as well as glycaemic effects. Renal function, contraindications, adverse effects, treatment burden and affordability/formulary factors remain important. Make shared decisions when changing treatment.
Safety and review
Look for hypoglycaemia, weight change, renal deterioration, treatment intolerance and medicines that no longer offer meaningful benefit. In frailty or multimorbidity, avoid chasing numerical targets at the expense of safety and quality of life. Use current retinal, foot, renal and cardiovascular complication pathways rather than treating HbA1c as the sole measure of good diabetes care.
